Home  |  Contact

Cellosaurus HTC-C3 (CVCL_1295)

[Text version]

Cell line name HTC-C3
Synonyms HTC/C3; HTC C3; HTCC3
Accession CVCL_1295
Resource Identification Initiative To cite this cell line use: HTC-C3 (RRID:CVCL_1295)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: ~100 hours (DSMZ); ~2 days (lot 04162002) (JCRB).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations BRAF p.Val600Glu (c.1799T>A) (PubMed=23833040; PubMed=30737244).
Heterozygous for TERT c.228C>T (-124C>T); in promoter (PubMed=23833040; PubMed=30737244).
TP53 p.Pro152Leu (c.455C>T) (PubMed=30737244).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.77
Native American0.3
East Asian, North74.17
East Asian, South22.11
South Asian0.65
European, North0.12
European, South1.88
Disease Thyroid gland undifferentiated (anaplastic) carcinoma (NCIt: C3878)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 44Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200; PubMed=30737244; RCB

Markers:
AmelogeninX
CSF1PO11,12
D2S133817,23
D3S135816
D5S81811,12
D7S82011,12
D8S117912,14
D13S31710,12
D16S5399,12
D18S5114,17
D19S43314
D21S1129,30
FGA21,22
Penta D9
Penta E11,16
TH016,7
TPOX8,9
vWA14,15

Run an STR similarity search on this cell line
Publications

PubMed=2196988; DOI=10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V
Enomoto T., Sugawa H., Inoue D., Miyamoto M., Kosugi S., Takahashi T., Kitamura N., Yamamoto I., Konishi J., Mori T., Imura H.
Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines.
Cancer 65:1971-1979(1990)

PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3
Satake S., Sugawara I., Watanabe M., Takami H.
Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.
Cancer Lett. 116:33-39(1997)

PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections DSMZ; ACC-580
JCRB; JCRB0164
JCRB; FDSC0042 - Discontinued
RCB; RCB0452
Cell line databases/resources CCLE; HTCC3_THYROID
Cell_Model_Passport; SIDM00496
CGH-DB; 58-1
Cosmic-CLP; 924151
DepMap; ACH-001350
GDSC; 924151
LINCS_LDP; LCL-1689
Ontologies CLO; CLO_0050946
Biological sample resources BioSample; SAMN01821636
BioSample; SAMN01821686
BioSample; SAMN03470940
Chemistry resources ChEMBL-Cells; CHEMBL3308747
ChEMBL-Targets; CHEMBL1075472
PharmacoDB; HTCC3_633_2019
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM1669916
Other Wikidata; Q54896604
Polymorphism and mutation databases Cosmic; 924151
Cosmic; 2009524
Cosmic; 2054084
Cosmic; 2613249
IARC_TP53; 1306
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number27